免疫检查点的fc效应器功能 阻断瘤学中的抗体
Romane Martineau1,2, Sandrine Susini2,3, Aurelien Marabelle1,2,3
1Université Paris Saclay, Le Kremlin-Bicetre, France.
Immunological reviews
|December 12, 2024
概括
针对CTLA-4和PD-1等免疫检查点的单克隆抗体可以治疗癌症. 它们的有效性取决于与Fc玛受体 (FcγR) 的相互作用,影响瘤学中的安全性和有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对免疫检查点的对抗性单克隆抗体 (mAbs) 已经改变了癌症治疗.
- 关键检查点包括CTLA-4,PD-1和LAG3,它们调节T细胞反应.
- FDA/EMA批准的抗体针对这些检查点,具有不同的机制和Fc玛受体 (FcγR) 亲和力.
研究的目的:
- 审查FcγR效应器功能对免疫检查点阻断剂的安全性和有效性的影响.
- 阐明FcγR相互作用如何影响瘤学中单克隆抗体的治疗结果.
主要方法:
- 对针对CTLA-4,PD-1和PD-L1.1的单克隆抗体现有文献的审查.
- 分析抗体同型 (IgG1,IgG2a,IgG4) 和它们的FcγR结合亲缘关系.
- 检查抗体效应因子的功能,如抗体依赖细胞介导的细胞毒性 (ADCC) 和抗体依赖细胞化 (ADCP).
主要成果:
- 抗CTLA-4 (ipilimumab,tremelimumab) 和一些抗PD-L1 (avelumab) 抗体具有高的FcγR亲缘关系,使ADCC/ADCP成为体内疗效至关重要的.
- 抗PD(L) 1抗体 (nivolumab, pembrolizumab, durvalumab, atezolizumab) 是为低FcγR亲和力而设计的,以优化纯检查点阻塞.
- FcγR效应器的功能与这些癌症免疫疗法的安全性和疗效性相关.
结论:
- 在癌症治疗中,FcγR效应器功能是免疫检查点阻断剂性能的关键决定因素.
- 定制FcγR亲和力对于优化针对免疫检查点的单克隆抗体的治疗指数至关重要.
相关概念视频
Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cytotoxic T Cells-mediated Immune Response
846
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
846
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
T Cell Types and Functions
951
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
951
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


